APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.
about
Onto better TRAILs for cancer treatmentPrinciples of antibody-mediated TNF receptor activationGetting TRAIL back on track for cancer therapyTRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells.Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display.Symmetry Controlled, Genetic Presentation of Bioactive Proteins on the P22 Virus-like Particle Using an External Decoration Protein.TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma.Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directionsTRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models.Caffeic acid phenethyl ester enhances TRAIL-mediated apoptosis via CHOP-induced death receptor 5 upregulation in hepatocarcinoma Hep3B cells.Key regulators of apoptosis execution as biomarker candidates in melanomaMultivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.An Apoptosis-Inducing Peptidic Heptad That Efficiently Clusters Death Receptor 5.IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer.Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy.Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.Developing TRAIL/TRAIL death receptor-based cancer therapies.STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.IgG-single-chain TRAIL fusion proteins for tumour therapy.Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells.Cytokeratin 8/18 protects breast cancer cell lines from TRAIL-induced apoptosis.A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor ImmunitySensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonismPromising Antineoplastic Actions of Melatonin
P2860
Q26768160-8ECA3BE8-03C8-4C5C-8BB0-209969225473Q26796270-2F8426C6-6465-44FB-B33E-E75015157F4FQ27027460-268DFEE5-E80E-46D8-8039-79E06C455EF5Q34557885-2C61F347-5E0F-4D94-89C5-625AB2460C5DQ35590091-34EBD252-078C-4A20-8028-F48EFEF61B72Q36892485-FF2EFADD-007C-402F-B53C-B651B727A064Q37012681-16DF8D05-6929-4A49-A7E3-38F0A4040226Q37141627-CED9768E-7487-46B3-84D8-A222FBB917ABQ37492231-DECDEE42-EF05-444B-8D21-607B2871922DQ37641600-E0E44738-AC17-485A-A843-5751B02ED414Q38340808-90973292-9A62-484B-8D4F-867F7463C446Q38750240-27548EDD-8351-43A2-9013-E1F8EB09A244Q38766692-8842A833-880B-47CA-9DEA-837093BD7347Q38866722-77686864-22BD-4F7E-887A-C55CAEA16664Q38931192-E89A22F3-B1B1-4B1B-A6F7-CD29934BAA9FQ39908453-081DAC09-5BB5-41C7-BA06-6AE3AE60D5CDQ41285625-E3D85DEC-7D76-47B7-88AC-7FBF53A75B9EQ50070105-09A4A44E-BB26-4587-B911-F21E753A41D9Q51760860-4EB39D59-3FC1-441D-8A40-B3D5EED431D0Q52579567-CBB4F943-2E27-4E17-AE19-21586176A57CQ53701901-4322E4A3-46F6-4BF0-8B23-4414140443E6Q54959839-C5CCDDA6-0336-4C7F-9A4C-A8217F6E5AB1Q54998541-13CF9241-BC58-4464-8B35-3C403B6B6D18Q55012569-32D63CEE-9DD6-4252-84DF-0A957FA2477AQ55101408-D8CBE79E-C767-43D2-8316-78C0358A6CE1Q57300170-16A60538-5E58-4C96-AD44-33B644CDFF71Q58547260-CE386A68-3C77-4CFB-828B-7D6CECB2CCD4Q58554204-EE8E7E2D-0D77-4BFE-A4C5-1024D677BF68
P2860
APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
APG350 induces superior cluste ...... oss-linking via Fcγ receptors.
@en
APG350 induces superior cluste ...... oss-linking via Fcγ receptors.
@nl
type
label
APG350 induces superior cluste ...... oss-linking via Fcγ receptors.
@en
APG350 induces superior cluste ...... oss-linking via Fcγ receptors.
@nl
prefLabel
APG350 induces superior cluste ...... oss-linking via Fcγ receptors.
@en
APG350 induces superior cluste ...... oss-linking via Fcγ receptors.
@nl
P2093
P1476
APG350 induces superior cluste ...... oss-linking via Fcγ receptors.
@en
P2093
Behnaz Ahangarian Abhari
Carmen Fischer
Christian Gieffers
Christian Merz
Harald Fricke
Jaromir Sykora
Marcus Branschädel
Meinolf Thiemann
Michael Kluge
Oliver Hill
P304
P356
10.1158/1535-7163.MCT-13-0323
P50
P577
2013-10-07T00:00:00Z